Ares Financial Consulting
EW icon

Ares Financial Consulting’s Edwards Lifesciences EW Stock Holding History

Ares Financial Consulting’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$21.3K Sell
247
-16
-6% -$1.42K 0.01% 404
2026
Q2 		$23.8K Buy
263
+16
+6% +$1.34K 0.02% 379
2026
Q1 		$20.1K Hold
247
– – 0.02% 395
2025
Q4 		$21.1K Buy
+247
New +$20.3K 0.02% 249

Other funds holding EW

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Mirova US
Mirova US Boston, Massachusetts $9.15B AUM 21.91% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Ares Financial Consulting's EW Position: Q3 2026 in Review

Ares Financial Consulting reduced its Edwards Lifesciences (EW) stake by 6.1% in Q3 2026, selling an estimated $1.42K and leaving 247 shares worth $21.3K. The position accounts for 0.01% of the portfolio, ranked #404.

Ares Financial Consulting first reported a position in EW in Q4 2025 and has held it in 4 quarters since. The position peaked at $23.8K in Q2 2026. 719 funds tracked by Wall St. Rank hold EW as of Q3 2026.

  • Ares Financial Consulting held 247 shares of Edwards Lifesciences worth $21.3K as of Q3 2026.
  • Ares Financial Consulting sold 16 Edwards Lifesciences shares in Q3 2026, an estimated $1.42K.
  • Edwards Lifesciences made up 0.01% of Ares Financial Consulting's portfolio in Q3 2026, its #404 holding.
  • Ares Financial Consulting first reported a position in Edwards Lifesciences in Q4 2025 and has held it in 4 quarters since.
  • Ares Financial Consulting's Edwards Lifesciences position peaked at $23.8K in Q2 2026.
  • 719 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.